Ultragenyx Pharmaceuticals Investigational New Drug Application For Triheptanoin For The Treatment Of Glucose Transporter Type-1 Deficiency Syndrome Is In Effect

Published: Dec 17, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NOVATO, Calif., Dec. 17, 2013 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, announced today that its Investigational New Drug (IND) application filing for triheptanoin (UX007) for the treatment of glucose transporter type-1 deficiency syndrome (Glut1 DS) is in effect. The IND allows the company to proceed with its clinical development program for triheptanoin in Glut1 DS in the United States. The company plans to initiate a Phase 2 trial studying triheptanoin in Glut1 DS in the first half of 2014.

Help employers find you! Check out all the jobs and post your resume.

Back to news